Market news

Colospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), today announced the successful completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform. The technology represents Colospan's second platform, expanding the innovation pipeline beyond its lead product, CG-100, and reinforcing Galmed's strategy of building a diversified portfolio of technologies addressing significant unmet needs in colorec

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced significant results from a pre-clinical study of a combination of Aramchol and Xtandi® (enzalutamide) for prostatic cancer.

Detailed price information for Galmed Pharmaceutica (GLMD-Q) from The Globe and Mail including charting and trades.

Galmed announced the development of a lipid nanoparticle formulation of Aramchol designed to target heart tissue, marking a potential expansion of the drug beyond its existing liver and gastrointestinal development programs. Key Investor TakeawaysGalmed (NASDAQ:GLMD) developed a novel cardiac-targeted formulation of Aramchol using lipid nanoparticles in collaboration with Barcode Nanotech.